Sandbox Reserved 1122: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 83: | Line 83: | ||
OF CHEMOTHERAPY RESISTANCE IN HUMAN SMALL CELL | OF CHEMOTHERAPY RESISTANCE IN HUMAN SMALL CELL | ||
LUNG CANCER CELL LINES]</ref> That’s why Bcl-2 is a prime target for new cancer therapies. | LUNG CANCER CELL LINES]</ref> That’s why Bcl-2 is a prime target for new cancer therapies. | ||
== Therapies targeting Bcl-2 == | |||
As a prime target for new cancer therapies, many new drugs target Bcl-2 in order to treat cancers. That’s the case of Genasense, which an antisens oligonucleotide drug. Its aim is to hybridises with Bcl-2 mRNA, thus avoiding its translation and the formation of the protein (even if further studies have shown limited results). Many other drugs are under development, each targeting Bcl-2 ( for example, Small molecule inhibitors, such as Fenretinide, down-regulating Bcl-2). Molecules directly interacting with the protein such as Gossypol are also studied, showing relatively good results. <ref>[http://clincancerres.aacrjournals.org/content/15/4/1126.full Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy ]</ref> | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
